United Kingdom
|
|
N/A
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
4th Floor
One Cavendish Place
London W1G 0QF
United Kingdom
+44 33 3023 7300
|
|
(Address including zip code of Principal Executive Offices)
|
|
|
|
Mereo Biopharma Group plc 2019
Equity Incentive Plan
Mereo Biopharma Group plc 2019
Non-Employee Equity Incentive Plan
|
|
(Full title of the plans)
|
|
|
|
|
Mereo US Holdings Inc.
251 Little Falls Drive
Wilmington, DE 19808
Telephone No.: +1 302 636 5400
(Name, address and telephone number,
including area code, of agent for service)
|
|
|
|
|
|
|
|
Copy to
:
|
|
|
Leo Borchardt
Veronica Wissel
Davis Polk & Wardwell LLP
450 Lexington Avenue
New York, New York 10017
+1 212 450 4000
|
|
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2
of the Exchange Act.
PART II
INFORMATION REQUIRED
IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents are incorporated
herein by reference:
(a)(i) The Annual Report on Form 20-F for
the year ended December 31, 2018, filed with the Commission on April 29, 2019.
(b) All reports filed pursuant to Section
13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) since the end of the fiscal
year covered by the Registrant’s Form 20-F referred to in clause (a)(ii) above; and
(c) The description of the Registrant’s
ordinary shares which is contained in the Registrant’s registration statement on Form 8-A, dated April 9, 2018 (Registration
No. 001-38452), including any amendment or report filed for the purpose of updating such description.
In addition, all documents subsequently
filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing
of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which
deregisters all securities then remaining unsold, including any Report of Foreign Private Issuer on Form 6-K submitted during such
period (or portion thereof) that is identified in such form as being incorporated by reference into this Registration Statement,
shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing
of such documents. The Registrant is not incorporating by reference any document or portion thereof, whether specifically listed
above or to be filed in the future, that is not deemed “filed” with the Commission.
Any statement contained in a document incorporated
or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration
Statement to the extent that a statement contained herein, (or in any other subsequently filed document which also is incorporated
or deemed to be incorporated by reference herein), modifies or supersedes such statement. Any such statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Item 5. Interests of Named Experts and Counsel.
Not applicable.
Item 6. Indemnification of Directors and Officers.
The Articles of Association of the Registrant
provide that the Registrant may indemnify the directors and
other officers of the Registrant in respect
of any proceedings, whether civil or criminal, brought against them by reason of their being directors or officers of the Registrant
and to the fullest extent permitted by the Companies Act 2006 of the United Kingdom (“CA 2006”).
Generally, under CA 2006, any provision
by which the Registrant directly or indirectly provides an indemnity (to any extent) for a director of the Registrant or of an
“associated company” (i.e., a company that is a parent, subsidiary or sister company of the Registrant) against any
liability attaching to him or her in connection with any negligence, default, breach of duty or breach of trust in relation to
the company of which he or she is a director is (subject to certain exceptions specified under CA 2006) void.
The Registrant has entered into a deed
of indemnity with each of its directors, the form of which was filed as Exhibit 10.26 to the Registrant’s registration statement
on Form F-4 (Registration No. 333-229351), as originally filed by the Registrant on January 25, 2019 and subsequently amended.
Except as prohibited by applicable law, these deeds of indemnity may require the Registrant, among other things, to indemnify its
directors for certain expenses, including attorneys’ fees, costs and expenses incurred by such directors with the prior written
consent of the Registrant in any action or proceeding arising out of their service as a director of the Registrant, or one of its
subsidiaries.
The Registrant maintains directors’
and officers’ insurance coverage, which, subject to policy terms and limitations, is expected to include coverage to reimburse
the Registrant for amounts that it may be required or permitted by law to pay directors or officers of the Registrant.
Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers or persons controlling the Registrant pursuant to the
foregoing provisions, the Registrant has been informed that in the opinion of the Commission such indemnification is against public
policy as expressed in the Securities Act and is, therefore, unenforceable.
Item 7. Exemption from Registration Claimed.
Not applicable.
Item 8. Exhibits.
The exhibits listed below in the “Exhibit
Index” are filed as a part of, or incorporated by reference into, this Registration Statement.
Item 9. Undertakings.
|
(a)
|
The undersigned Registrant hereby undertakes:
|
(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i) To
include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii) To
reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high
end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if,
in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering
price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;
(iii) To
include any material information with respect to the Plans not previously disclosed in this Registration Statement or any material
change to such information in this Registration Statement;
provided
,
however
,
that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment
by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section
13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.
(2) That,
for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial
bona fide
offering thereof.
(3) To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.
(b) The
undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing
of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing
of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference
in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be the initial
bona fide
offering thereof.
(c) Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons
of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the
Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In
the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred
or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant
will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will
be governed by the final adjudication of such issue.
POWER OF ATTORNEY
KNOW ALL PERSONS
BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Dr. Denise Scots-Knight and Richard
Jones and each of them, individually, as his or her true and lawful attorney-in-fact and agent, with full power of substitution
and resubstitution, for him or her and in his or her name, place and stead in any and all capacities, in connection with this Registration
Statement, including to sign in the name and on behalf of the undersigned, this Registration Statement and any and all amendments
thereto, including post-effective amendments and registrations filed pursuant to Rule 462 under the U.S. Securities Act of 1933,
as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities
and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every
act and thing requisite and desirable to be done in and about the premises, as fully to all intents and purposes as he or she might
or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may
lawfully do or cause to be done by virtue hereof.
Pursuant to the
requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in
the capacities and on the dates indicated:
Signature
|
|
Title
|
Date
|
/s/ Denise Scots-Knight
|
|
Chief Executive Officer
|
May 21, 2019
|
Dr. Denise Scots-Knight
|
|
(Principal Executive Officer) and Director
|
|
|
|
|
|
/s/ Richard Jones
|
|
Chief Financial Officer
|
May 21, 2019
|
Richard Jones
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
/s/ Peter Fellner
|
|
Chairman (non-executive) of the Board of Directors
|
May 21, 2019
|
Dr. Peter Fellner
|
|
|
|
|
|
|
|
/s/ Peter Bains
|
|
Non-executive Director
|
May 21, 2019
|
Peter Bains
|
|
|
|
|
|
|
|
/s/ Paul Blackburn
|
|
Non-executive Director
|
May 21, 2019
|
Paul Blackburn
|
|
|
|
|
|
|
|
/s/ Anders Ekblom
|
|
Non-executive Director
|
May 21, 2019
|
Dr. Anders Ekblom
|
|
|
|
|
|
|
|
/s/ Kunal Kashyap
|
|
Non-executive Director
|
May 21, 2019
|
Kunal Kashyap
|
|
|
|
|
|
|
|
/s/ Deepika R. Pakianathan
|
|
Non-executive Director
|
May 21, 2019
|
Deepika R. Pakianathan
|
|
|
|
|
|
|
|
/s/ Michael S. Wyzga
|
|
Non-executive Director
|
May 21, 2019
|
Michael S. Wyzga
|
|
|
|
|
|
|
|
AUTHORIZED REPRESENTATIVE
Pursuant to the requirements of the Securities
Act of 1933, as amended, this Registration Statement has been signed by the undersigned, the duly authorized representative in
the United States of Mereo BioPharma Group plc, on May 21, 2019.
Mereo US Holdings Inc.
|
|
|
|
|
|
By:
|
/s/ Denise Scots-Knight
|
|
|
Name:
|
Dr. Denise Scots-Knight
|
|
|
Title:
|
President
|
|